News | May 30, 2024
Merck to acquire EyeBio for US$ 1.3 billion upfront payment
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Acquisition includes Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration
Asahi Kasei will offer to acquire all of the ordinary shares of Calliditas
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Subscribe To Our Newsletter & Stay Updated
